HC Wainwright Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $92.00
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its target price raised by analysts at HC Wainwright from $82.00 to $92.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 44.02% from the company’s previous close. […]
More Stories
Heck Capital Advisors LLC Purchases New Holdings in NVIDIA Co. (NASDAQ:NVDA)
Heck Capital Advisors LLC purchased a new stake in NVIDIA Co. (NASDAQ:NVDA – Free Report) in the fourth quarter, according...
NVIDIA Co. (NASDAQ:NVDA) Stake Increased by Azzad Asset Management Inc. ADV
Azzad Asset Management Inc. ADV grew its stake in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) by 0.5% during...
Fidelity D & D Bancorp Inc. Cuts Holdings in NVIDIA Co. (NASDAQ:NVDA)
Fidelity D & D Bancorp Inc. reduced its holdings in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) by 5.5%...
Armis Advisers LLC Invests $4.22 Million in NVIDIA Co. (NASDAQ:NVDA)
Armis Advisers LLC bought a new position in NVIDIA Co. (NASDAQ:NVDA – Free Report) during the 4th quarter, according to...
Brooklyn FI LLC Sells 150 Shares of NVIDIA Co. (NASDAQ:NVDA)
Brooklyn FI LLC decreased its position in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) by 3.9% in the 4th...
NVIDIA Co. (NASDAQ:NVDA) Shares Purchased by Employees Retirement System of Texas
Employees Retirement System of Texas boosted its position in NVIDIA Co. (NASDAQ:NVDA – Free Report) by 2.2% in the 4th...